Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Monopar Therapeutics Inc. Common Stock

MNPR

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.

Last trade $71.02
Day change -$0.95 (-1.32%)
Day range $69.27 – $75.05
Volume 97,643
Market cap $488M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$487.72M
Price / earnings
—
Price / book
3.84×
Price / sales
—
EV / sales
—
EV / EBITDA
-17.07×

Profitability

Earnings per share
-$3.04
Return on assets
-15.82%
Return on equity
-16.21%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
43.55×
Quick ratio
43.55×
Cash ratio
17.65×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.27M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for MNPR, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$3.03M$1.88M$1.74M$2.21M$1.5M$1.5M$1.58M$1.15M
Research and development$4.44M$4.77M$3.49M$3.94M$2.59M$1.73M$1.64M$9.92M
Total operating expenses$7.47M$6.64M$5.23M$6.16M$4.09M$3.23M$3.22M$11.07M
Operating income-$7.47M-$6.64M-$5.23M-$6.16M-$4.09M-$3.23M-$3.22M-$11.07M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$6.2M-$5.31M-$3.89M-$5.2M-$3.44M-$2.45M-$2.62M-$10.93M
Income taxes$0$0$0$0$0$0$0$0
Net income-$6.2M-$5.31M-$3.89M-$5.2M-$3.44M-$2.45M-$2.62M-$10.93M
Net income attributable to common shareholders-$6.2M-$5.31M-$3.89M-$5.2M-$3.44M-$2.45M-$2.62M-$10.93M
EBITDA-$7.47M-$6.64M-$5.23M-$6.16M-$4.09M-$3.23M-$3.22M-$11.07M
Basic earnings per share-$0.72-$0.62-$0.46-$0.61-$0.48-$0.35-$0.38-$2.21
Diluted earnings per share-$0.72-$0.62-$0.46-$0.61-$0.48-$0.35-$0.38-$2.21

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026

Monopar Therapeutics announced Phase 2 trial results for ALXN1840 (tiomolibdate choline) in treatment-experienced Wilson disease patients. The study demonstrated stabilization or improvement in liver pathology across multiple histologic measures, significant neurologic improvements in UWDRS scores, and improved quality of life. The drug was generally well tolerated with mostly Grade 1-2 adverse events.

GlobeNewswire Inc.

Monopar Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates

Monopar Therapeutics announced Q1 2026 financial results with cash reserves of $137.5 million and a net loss of $3.9 million. The company presented Phase 3 FoCus trial data showing ALXN1840 (tiomolibdate choline) demonstrated greater neurologic benefit versus standard-of-care in Wilson disease patients. The NDA submission to the FDA remains on track for mid-2026, with new Chief Commercial and Strategy Officer Susan Rodriguez leading commercial readiness activities.

GlobeNewswire Inc.

Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

Monopar Therapeutics announced 2025 financial results with a net loss of $13.7 million and cash reserves of $140.4 million expected to support operations through at least December 2027. The company plans to submit a New Drug Application for ALXN1840 in mid-2026 for Wilson disease treatment, supported by positive clinical data presentations and FDA interactions. The company also strengthened its leadership team and balance sheet through a $91.9 million public offering.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Aug 13, 20241-for-5reverse split